A commercially available luminescence enhanced enzyme immunoassay (Amerlite -Amersham International) for carcinoembryonic antigen (CEA) was compared with an established enzyme immunoassay (Monoclonal 1-step Assay -Abbott Laboratories). A reference ränge for healthy blood donors (n = 272) was established for both kits. The blood donors were not separated into smokers and non-smokers, but were excluded from the reference group if they showed abnormal aminotransferase or -glutamyltranspeptidase serum values. Twenty eight donors were excluded in this way. The test group consisted of 130 known tumour patients, and included pre-and post-operative serum samples. Normal and elevated CEA values were present. All sera were negative for HBsAg, anti-HBsAg and anti-HIV äs determined with commercial enzyme immunoassays used routinely in the blood bank. **
Introduction
Although the first immunoassays using luininescent labels were published over a decade ago (1) , the commercial exploitation of these methods has only recently led to the production of immunoassay kits using luminescent detection.
This brief communication reports the preliminary performance of a luminescence enhanced enzyme immunoassay for the determination of carcinoembryonic antigen (CEA). The method used for the routine CEA determination, an enzyme immunoassay, was used äs a comparison (2) .
Serum samples were obtained from healthy blood donors and from known tumour-bearers.
Horseradish peroxidase was used äs label in both cases, the enzyme immunoassay using 0-phenylene diamine äs chromogen, the luminescence enhanced immunoassay having an aryl hydrazide and an enhancer äs luminogen. In both cases, the peroxidase functioned äs an enzyme, the signal being proportional to the amount of enzyme bound to the antigenantibody complex, i.e. to the amount of nascent oxygen produced. This is in contrast to "conventional" chemiluminescence immunoassays using aryl hydrazide labels, where the hydrogen peroxide is in excess, and the amount of immobilised luminogen determines the light Output (3).
Materials and Methods

Apparatus and Kits
The enzyme immunoassay was purchased from Abbott Diagnostics (Wiesbaden Delkenheim, D) and was the monoclonal l-step CEA-EIA kit. The assay was perfonned manually and was measured in a microprocessor-controlled spectrophotometer (Quantum I -Abbott).
The luminescence enhanced immunoassay, supplied by Amersham Buchler (Braunschweig, D), was the Amerlite CEA monoclonal antibody assay. Pipetting of samples was performed manually, other steps being performed automatically. The Amerlite System was a closed System äs far äs measurement and data-processing were concerned. At the time of writing, laboratory-own assays could not be perfonned using the system. The Abbott kit used the familiär ball and tray System, while the Amerlite kit used coated well-strips which were fitted into microtitre plates.
Samples
Blood donors were chosen äs the reference group, excluding those who had abnormal aminotransferase and -glutamyltranspeptidase values. All were negative for HBsAg, anti HBsAg and anti HIV, äs determined by modern enzyme immunoassays. Twenty eight out of 300 blood donors were excluded from the study äs a result of the above screening procedure. No discrimination was made between smokers and non-smokers.
Serum from tumour patients was taken before and after Operation, no discrimination being made in the 130 patients studied. The sera inclüded normal and clevated CEA concentrations.
Statistics
Non-parametric statistics were used throughout, äs the distribution of data in both groups was non-Gaussian. Tests used inclüded the Mann-Whitney U-test'foith z-transformation and the Wilcoxon signed rank test for matched pairs with c-alpha calculation. The confldence limits for each group were given äs the relevant percentile together with the median value. The ratio mean/median was used äs an index of the data distribution. In all cases, the enzyme immunoassay (Abbott) was entered äs x, the luminescence enhaneed enzyme immunoassay (Amersham) äs y.
Results
The assay schemes are shown in tables l a and l b. The distribution of serum concentrations in 272 healthy blood donors are shown in table 2 a, those for the 130 tumour patients in table 2b. Table 2c shows the correlation between both groups. Relevant quality control parameters are given in table 3. The light index values of the Standard curve from the luminescence enhanced enzyme immunoassay are shown in table 4 a. (The light index values of the samples reflect the light intensity of the peroxidaselüminogen mixture in each well. They act äs a quality control parameter inasmuch äs when they lie outside a defined region, the latter being given by the prö-ducer, accuracy and precision can no longer be guaranteed.) Although the light intensity decreases with time, due to the depletion of Substrate and/or inactiv ation of the peroxidase,> the values read off the Standard curve were stable over 60 minutes after addition of the signal reagent, even though the printout showed the flag "pöor cürVe" when the light index feil below the lower limit of acceptance, which in this case was 3.0. These results are summarised in table 4b. Concurrence of values of samples measured in both kits are shown for the 130 tumour patients in table 5. Table 6 a shows the effect of diluting the first Standard with the zero Standard to attempt to define the lower detection limit of each assay. In the case of the Amerlite assay, this was non-linear. Table  6 b shows the effect of measuring the Standards and control sera from one kit äs samples in the contfalateral kit. Table 6c shows the results of diluting the Amersham 3 §/1 Standard with a serum which repeatedly gave an undectable value in the Abbott assay. After cörrectmg the 1:2 dilution for an "exogenous CEA" pf 0.04 §/1, the expected values for the serial dilution were obtained down to ca. 0.2 §/1. The lower limits of detection were set at 0.25 §/1, all values below this being recorded äs not deteetable. 
Disc ssion
The combination of an enzyme label and luminogen s signal has been described for both dehydrogenases (4) and for peroxidases (l, 5). The enhancement and stabilisation of the light signal is system-specific and cannot be transferred to pther Systems, even when these use the same components in a different assay form (3).
The enhancement and stabilising Systems have been patented (5) s far s the peroxidase/acykaryl hydrazide system is concerned. As the peroxidase used in the Amerlite kit serves s an enzyme, and not s a "one-ofF' catalyst s in the conventional chemil minescence assay (6), the light signal depends upon the aetivity of the enzyme. The light signal can be enhanced by addition of compounds such s 4-iodophenol and ZMuciferin (5).
Tables 4 a and 4b show that although the light intensity decreases with time, useable Standard curves are produced, even for times well in excess of those given by the manufacturer between addition of signal reagent and measurement. gives Values inside the established reference r nge, whereas the other one gives elevated values. Statistically speaking, the results from both kits differed significantly, which was reflected for example by the difference in the reference ranges.
Both kit protocols contained tables of expected values for healthy and ill patients. For the Amersham kit, data provided on 300 blood donors, including smokers and non-smokers, showed that 98.6% had values under 5.0 μg/l. This coincides well with the values found in this study (98.4% of values less than 5 μg/l).
Tab. 3. Intra-and interassay quality control data.
Intra-assay data. Abbott EIA -mean coefficient of Variation from compound precision profiles from 30 assays (n = 527 data pairs, concentration ränge 0.3-10 g/l) = 5.75%.
Amersham LEIA -mean coefficient of Variation from compound precision profiles from 20 assays (n = 344 data pairs, concentration ränge 0.3-10 g/l) = 2.97%. The 40 and 60 minute read-outs gave the flag "poor curve" äs a warning, äs the light-index feil under the limit set in the Programme (here for CEA 3.00) Tab The values were statistically significant in each case (p < 0.001), but this had no clinical implications and showed that differences were due to curve fitting and not to individual differences in the Signals from each well. The sensitivity of the Amerlite kit was given s "better than 0.5 μ §/Ρ, that for the Abbott kit s "calculated to be approximately 0.5 μ §/1". The results of this study confirm the Abbott results and support the Amersham Claims (see tab. 6 a & 6 c). Table 6 b demonstrates once again, that kit Standards, even though calibrated against the same international reference material (here WHO 73/601), are not interchangeable. This is shown most dramatically for the highest Amersham Standard (60 μg/l) which gave a value of less than 0.5 μg/l when measured s sample in the Abbott kit. This value was repeatedly obtained, and so a mistake in the measurement itself can be excluded. The question of a high dose hook effect can be ruled out s sera with CEA levels above 1500 μg/l still gave an optical density reading in the Abbott kit above that of the highest Standard (80 μg/l).
To conclude, it can be shown that both kits are similar in performance, and that the luminescence enhanced enzyme immunoassay kit from Amersham International can take its place alongside other established non-radioisotopic methods. However, like its competitors, the luninescence enhanced enzyme immunoassay cannot be used s a "screening method", but only in the follow-up and control of tumour patients.
